JP2015517504A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517504A5
JP2015517504A5 JP2015511877A JP2015511877A JP2015517504A5 JP 2015517504 A5 JP2015517504 A5 JP 2015517504A5 JP 2015511877 A JP2015511877 A JP 2015511877A JP 2015511877 A JP2015511877 A JP 2015511877A JP 2015517504 A5 JP2015517504 A5 JP 2015517504A5
Authority
JP
Japan
Prior art keywords
chelate complex
seq
pharmaceutical composition
interferon
oligonucleotide consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517504A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2013/050379 external-priority patent/WO2013170386A1/en
Publication of JP2015517504A publication Critical patent/JP2015517504A/ja
Publication of JP2015517504A5 publication Critical patent/JP2015517504A5/ja
Pending legal-status Critical Current

Links

JP2015511877A 2012-05-18 2013-05-17 オリゴヌクレオチドキレート錯体−ポリペプチド組成物および方法 Pending JP2015517504A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US61/648,711 2012-05-18
US201261695035P 2012-08-30 2012-08-30
US61/695,035 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (2)

Publication Number Publication Date
JP2015517504A JP2015517504A (ja) 2015-06-22
JP2015517504A5 true JP2015517504A5 (enExample) 2016-07-07

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511877A Pending JP2015517504A (ja) 2012-05-18 2013-05-17 オリゴヌクレオチドキレート錯体−ポリペプチド組成物および方法

Country Status (34)

Country Link
US (1) US9492506B2 (enExample)
EP (1) EP2849798B1 (enExample)
JP (1) JP2015517504A (enExample)
KR (1) KR102068109B1 (enExample)
CN (1) CN104349793B (enExample)
AU (1) AU2013262416B2 (enExample)
BR (1) BR112014028654A2 (enExample)
CA (1) CA2873529C (enExample)
CL (1) CL2014003134A1 (enExample)
CO (1) CO7131387A2 (enExample)
CR (1) CR20140527A (enExample)
CY (1) CY1124345T1 (enExample)
DK (1) DK2849798T3 (enExample)
DO (1) DOP2014000264A (enExample)
EA (1) EA035967B1 (enExample)
EC (1) ECSP14027694A (enExample)
ES (1) ES2873844T3 (enExample)
HR (1) HRP20210840T1 (enExample)
HU (1) HUE054875T2 (enExample)
IL (1) IL235548B (enExample)
LT (1) LT2849798T (enExample)
MX (1) MX346239B (enExample)
MY (1) MY168778A (enExample)
NZ (1) NZ703095A (enExample)
PH (1) PH12014502551B1 (enExample)
PL (1) PL2849798T3 (enExample)
PT (1) PT2849798T (enExample)
RS (1) RS62030B1 (enExample)
SG (1) SG11201407599SA (enExample)
SI (1) SI2849798T1 (enExample)
SM (1) SMT202100319T1 (enExample)
TW (1) TWI635864B (enExample)
WO (1) WO2013170386A1 (enExample)
ZA (1) ZA201408674B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
CN104837501B (zh) 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
KR20170029577A (ko) * 2014-07-10 2017-03-15 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20200147124A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
EP4728073A1 (en) * 2023-06-16 2026-04-22 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
EA008940B1 (ru) * 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
CN1997666A (zh) * 2003-02-26 2007-07-11 印特缪恩股份有限公司 聚乙二醇修饰的干扰素组合物及其使用方法
CN1893978A (zh) * 2003-10-27 2007-01-10 沃泰克斯药物股份有限公司 用于hcv治疗的组合
WO2006042418A1 (en) * 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
EP1928498A4 (en) * 2005-09-29 2009-11-11 Cell Biosciences Inc S METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
US20090215873A1 (en) * 2005-09-29 2009-08-27 Andrew Vaillant Therapeutic Molecules and their Uses
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
NZ585784A (en) * 2007-12-13 2012-09-28 Alnylam Pharmaceuticals Inc siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
ES2651308T3 (es) * 2009-10-16 2018-01-25 Glaxo Group Limited Inhibidores antisentido de HBV
JP5775581B2 (ja) * 2010-08-20 2015-09-09 レプリコール インコーポレーティッド オリゴヌクレオチドキレート錯体
CN104837501B (zh) 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法

Similar Documents

Publication Publication Date Title
JP2015528449A5 (enExample)
JP2010503396A5 (enExample)
JP2016503800A5 (enExample)
JP4413996B2 (ja) 抗ｂ型肝炎ウィルス活性を有するヌクレオシド
HRP20201953T1 (hr) Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b
JP2006516949A5 (enExample)
US6566344B1 (en) β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
JP2004513070A5 (enExample)
TWI620568B (zh) 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
JP2013507439A5 (enExample)
JP2010514768A (ja) ウイルス感染の治療のための化合物、及び医薬組成物
JP2015512860A5 (enExample)
JP2002522552A (ja) Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド
WO2014165704A1 (en) Hepatitis c viral infection treatment using a combination of compounds
JP2013522302A5 (enExample)
JP2016531144A5 (enExample)
CA2498731A1 (en) .beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
JP2004533401A5 (enExample)
CN103906759A (zh) 用于治疗病毒感染的化合物和药物组合物
HRP20231400T1 (hr) Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
TWI635864B (zh) 寡核苷酸螯合複合物－多肽組合物及方法
CN104968673A (zh) 融合多肽及使用方法
Bruno et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of SPRINT-2 and RESPOND-2 studies
JP7712982B2 (ja) 融合ポリペプチドおよび使用方法
JP2010520921A5 (enExample)